Cash & Marketable Securities Up 54 Percent Sequentially; Revenue Grows 6
Percent Year-Over-Year
SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Biosite Incorporated
(Nasdaq: BSTE) today reported financial results for the first quarter of
2007 highlighted by increases in revenue and cash. The Company also
provided an update on clinical trials for several potential new products.
Key Financial Results
* Cash generated from operations was $32.3 million in the first quarter of
2007, raising Biosite's cash and marketable securities balance to $98.9
million, a 54 percent increase over its cash and marketable securities
balance at December 31, 2006.
* Revenues for the first quarter of 2007 totaled $83.7 million, a 6
percent increase from $79.3 million in the comparable period of 2006. As
expected, growth resulted primarily from sales of Biosite's non-BNP
cardiovascular products and international sales, which increased 43
percent and 33 percent, respectively, on a year-over-year basis.
Year-over-year sales of the Triage(R) BNP Test products decreased 1
percent in the quarter. The decrease resulted from an anticipated
decline in U.S. hospital sales of the product partially offset by growth
in international and physician office sales, which increased 40 percent
and 12 percent, respectively. The Company attributed the decline in U.S.
hospital sales to an expected decline in the average price of the
product.
* For the first quarter of 2007, GAAP diluted earnings per share was
$0.66, compared with $0.68 for the first quarter of 2006. As previously
reported, Biosite's 2006 first quarter earnings per share was favorably
affected by the resolution of certain tax contingencies amounting to
$0.05 per diluted share following the completion of an Internal Revenue
Service audit of certain prior years.
* GAAP operating income for the first quarter of 2007 was $18.1 million.
In the comparable period of 2006, GAAP operating income was $18.5
million.
Following are financial highlights pertaining to revenues and cash flow
for the three months ended March 31, 2007 and 2006:
($ in 000's)
Three months ended
3/31/07 3/31/06 Change
Triage BNP Test sales $51,965 $52,564 (1%)
Other cardiovascular
product sales 17,362 12,106 43%
Other product sales 13,153 13,487 (2%)
Total product sales 82,480 78,157 6%
Total revenues 83,749 79,332 6%
Cash flow from operations $32,296 $31,025
Cash used for
stock repurchases $-- 30,000
3/31/07 12/31/06 Change
Cash and marketable
securities balance $98,857 $64,229 54%
"The year is off to a sound start driven by 81 percent combined
year-over- year growth in sales of our Triage Profiler Panel products and
Triage D-Dimer Test along with strong results in physician office and
international markets," said Kim Blickenstaff, Biosite's chairman and chief
executive officer. "We believe this reflects efforts to diversify our
revenue base and to capitalize on opportunities that exist for newer tests
addressing important areas of cardiovascular medicine, such as acute
coronary syndromes and pulmonary embolism."
Research and Development
In the area of research and development, Biosite continued to advance
several projects related to products currently under development:
* Activities relating to the clinical validation studies for the Triage
MPO Test and a next generation Triage CardioProfiler(R) Panel continued
to progress in the first quarter of 2007. The Company expects to file
a Premarket Notification 510(k) submission with the U.S. Food and Drug
Administration early in the third quarter of 2007 for the prognostic use
of myeloperoxidase (MPO.) Plans aimed at international commercialization
of the next generation Triage CardioProfiler Panel are also underway.
The Company's objective is to obtain CE marking for the product by
mid-year 2007 and to immediately launch a post-market evaluation study
to support future clinical publications.
The next generation Triage CardioProfiler Panel is designed to combine
the cardiovascular markers on the present test panel with MPO and to
incorporate Biosite's MultiMarker Index(TM) Value algorithm. MPO is
believed to be useful as an aid in the early diagnosis of myocardial
infarction and could signal risk for heart disease or heart attack in
patients with chest pain or acute coronary syndromes.
* Biosite also confirmed that the training study for its Triage NGAL Test
was launched in the first quarter of 2007. The Company intends to file
for CE marking of that product early in the third quarter of 2007. The
Triage NGAL Test is being developed as an aid in the prognosis of kidney
injury following cardiovascular surgery.
* As previously reported, preliminary data related to the Triage Sepsis
Panel were presented at the 27th International Symposium on Intensive
Care and Emergency Medicine. The data showed that the panel, made up of
the biomarkers neutrophil gelatinase-associated lipocalin (NGAL), c-
reactive protein (CRP) and macrophage inflammatory protein-3 (MIP-3),
may be a clinically useful tool in the assessment of risk of sepsis
progression within 72 hours of patients presenting to the emergency
department and meeting the diagnostic criteria for sepsis.
* Biosite said that patient enrollment for the Triage Sepsis Panel
validation study is on track to commence in May 2007. The study is aimed
at generating data to support a U.S. regulatory submission. A filing for
CE marking of the product is expected to be submitted in the third
quarter of 2007.
* The pilot feasibility trial for a Triage BNP Test fingerstick device has
been successfully completed and the validation study is anticipated to
start later this year, following completion of development.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions. The
Biosite(R) Triage(R) rapid diagnostic tests are used in more than 70
percent of U.S. hospitals and in more than 60 international markets.
Information on Biosite can be found at http://www.biosite.com.
Investor Conference Call
Biosite will host an investor conference call to discuss financial
results and research and development progress. The call will take place
today, April 24, 2007, at 1:30 p.m. Pacific. A live webcast of the call can
be accessed via the Internet at http://www.biosite.com. The phone number is (617)
213-8832. The conference call code for the live call is 60807471. The call
will be archived on the Biosite website for at least 21 days. The phone
replay number is (888) 286-8010. International callers, please dial (617)
801-6888. Please reference the conference call code 50964236.
Forward Looking Statements
This press release contains forward-looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed
or implied by such statements. Examples of forward-looking statements are
financial targets and growth objectives and also include but are not
limited to statements that are preceded by, followed by, or that include
the words "will"; "believes"; "should"; "intend"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements. Forward-looking statements
in this press release include statements regarding the Company's expected
financial performance for the 2007 fiscal year, such as anticipated
revenues, operating margins and earnings per share, the Company's ability
to achieve growth targets in the international and physician office
markets, the Company's ability to maintain market share for cardiovascular
testing, the Company's plans to initiate and complete proposed studies for
the Triage MPO Test, the next generation Triage CardioProfiler Panel, the
Triage NGAL Test, the Triage Sepsis Panel and the Triage BNP fingerstick
device, as well as the Company's plans to submit United States and foreign
regulatory filings for those potential new products when expected. Risks
and uncertainties include risks associated with Biosite's ability to
commence and complete clinical trials as currently planned, Biosite's
ability to obtain regulatory approvals and complete other pre-market
activities needed to launch new products as currently planned, Biosite's
ability to manufacture new products on a commercial scale and in accordance
with acceptable quality standards, Biosite's ability to effectively promote
and market acceptance of any new products, the continued growth of the BNP
market generally, including the physician office market, the Company's
ability to effectively expand sales activities outside the United States,
and other risks associated with changing market conditions and the effect
of competition from companies with greater capital and resources, including
the impact on market pricing for BNP testing generally. Other risks that
should be considered are detailed in the Company's most recent Annual
Report on Form 10- K and subsequent SEC filings. The Company disclaims,
however, any intent or obligation to update these forward-looking
statements. Copies of the Company's SEC filings are available from the
Investor Relations department or from the Company's website.
Biosite(R), Cardio Profiler(R), Triage(R) and New Dimensions in
Diagnosis(R) are registered trademarks of Biosite Incorporated. MultiMarker
Index(TM) is a trademark of Biosite Incorporated.
Biosite Incorporated
Unaudited Statements of Income Data - GAAP
(in thousands, except per share data and margins)
Three months ended
March 31,
2007 2006 % Change
Total revenues:
Product sales $82,480 $78,157 6%
Contract revenue 1,269 1,175 8%
Total revenues 83,749 79,332 6%
Gross margin on product sales 69% 70%
Operating expenses:
Cost of product sales 25,565 23,105 11%
Selling, general and administrative 26,552 23,966 11%
Research and development 13,568 13,698 (1%)
License and patent disputes -- 41 (100%)
Total operating expenses 65,685 60,810 8%
Operating income 18,064 18,522 (2%)
Operating income as % of total revenue 22% 23%
Interest and other income, net 693 1,248 (44%)
Income before provision
for income taxes 18,757 19,770 (5%)
Provision for income taxes (7,472) (7,213) 4%
Net income $11,285 $12,557 (10%)
Diluted earnings per share $0.66 $0.68 (3%)
Diluted shares used in calculating
per share amounts 17,060 18,601
Share-based compensation expense for stock options and the employee stock
purchase plan recorded in accordance with FAS 123R for continuing
operations:
Cost of product sales $773 $222 248%
Selling, general and administrative 3,069 4,022 (24%)
Research and development 1,565 1,810 (14%)
Subtotal $5,407 $6,054 (11%)
Tax benefit (1,736) (1,639) 6%
Total $3,671 $4,415 (17%)
Biosite Incorporated
Selected Product Data
(in thousands, except margins and %'s)
Sales by Product:
Q1 2006 Q2 2006 Q3 2006 Q4 2006 Q1 2007
Triage(R) Drugs of
Abuse Products $11,547 $10,464 $11,444 $10,836 $10,783
Triage Cardiac Panel 6,616 7,188 6,902 7,606 7,440
Triage BNP Tests 52,564 50,678 45,531 47,620 51,965
Triage Profiler Products 4,036 4,598 5,735 5,743 7,748
Triage D-Dimer Test 1,417 1,450 1,616 1,852 2,133
Triage Parasite Panel 286 337 377 360 320
Triage C. difficile Panel 1,029 1,088 1,022 977 1,272
Triage Meters 625 539 458 602 778
Triage Stroke Panel (EU) 37 30 26 25 41
Total Product Sales $78,157 $76,372 $73,111 $75,621 $82,480
International Sales:
Q1 2006 Q2 2006 Q3 2006 Q4 2006 Q1 2007
International Sales as %
of Product Sales 14% 15% 14% 16% 18%
BNP International Sales
as % of BNP Total Sales 11% 11% 10% 13% 15%
Margin by Product Type
(a), (b):
Q1 2006 Q2 2006 Q3 2006 Q4 2006 Q1 2007
Triage Drugs of Abuse
Product Line 79% 77% 73% 78% 78%
Triage Cardiovascular
Product Line (incl. BNP) 71% 70% 68% 69% 70%
(a) These margins do not include all products. The Triage Meters, Triage
Micro Product Line and Triage Stroke Panel are not included.
(b) Includes the impact of FAS 123R, which relates to the expensing of
non-cash stock-based compensation, beginning the first quarter of 2006
Biosite Incorporated
Unaudited Balance Sheet Data - GAAP
(in thousands)
March 31, 2007 December 31, 2006
Unaudited
Assets
Cash, cash equivalents & marketable
securities $98,857 $64,229
Accounts receivable 33,157 33,613
Inventories 32,729 33,154
Other current assets 13,700 14,603
Total current assets 178,443 145,599
Property, equipment and leasehold
improvements, net 157,658 157,945
Patents and license rights, net 8,873 9,399
Other assets 15,307 13,644
Total assets $360,281 $326,587
Liabilities and Stockholders' Equity
Current liabilities $39,793 $34,669
Long-term liabilities 13,474 11,763
Stockholders' equity 307,014 280,155
Total liabilities and
stockholders' equity $360,281 $326,587
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
http://www.prnewswire.com/comp/116737.html /
CONTACT:
Nadine Padilla, VP, Corporate & Investor
Relations of Biosite Incorporated, +1-858-805-2820,
npadilla@biosite.com
|
